The Neoantigen Registration Crisis: Why Your Cancer-Fighting T-Cells Now Need a Birth Certificate and Three Reference Letters Before They Can Fight Tumors
WASHINGTON — In a stunning turn of events for the cancer-fighting community, your immune system’s most valuable warriors—neoantigen-specific T-cells—are now being held hostage by a regulatory nightmare that threatens to delay every breakthrough immunotherapy by an average of 47 “administrative processing days.”
The Problem: T-Cells Without Proper Documentation
At the recent AACR 2026 Annual Meeting, researchers reported on KIR-CAR T-cell therapy trials for patients with advanced ovarian cancer, mesothelioma, and bile duct cancer. While the science is revolutionary—these cells were shown to be “safe, with increasing efficacy corresponding to higher doses”—the accompanying paperwork is reportedly “completely unmanageable.”